MDRNA Inc. (Nasdaq: MRNA) received an allowance letter from the patent office for its proprietary method of targeting peptide technology. Shares of the biotechnology firm leaped 29 cents to $1.30.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.